Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer-results from a pilot study.

To report the results of a pilot study on the prognostic value of a newly identified actin-binding protein, thymosin beta-15 (Tbeta15), in predicting prostate-specific antigen (PSA) and bone failure in patients with Gleason 6/10 clinically localized prostate cancer. Thirty-two patients (median age 70 years) with clinically localized, moderately differentiated (Gleason 6/10) prostate cancer treated by external beam radiotherapy alone (68.4 Gy) with available paraffin blocks at the Massachusetts General Hospital were evaluated for this pilot study. All patients had clinical Stage M0 disease at initial presentation, which was documented by bone scan (T1c-4,NX). Their corresponding biopsy specimens were stained immunohistochemically for Tbeta15, which was then correlated with the clinical outcome in a blinded manner. The median follow-up was 6 years (range 1 to 19) for all of the patients. The outcomes of the 32 patients can be grouped into three categories: patients with no evidence of disease (n = 11), patients with PSA failure without documented bone failure (n = 11), and patients with PSA failure and documented bone failure (n = 10). Tbeta15 staining intensity strongly correlated with clinical outcome. Of those patients whose specimens stained 3+ (strongest staining), 62% developed bone failure compared with 13% of those patients whose specimens stained 1+ (weakest staining) (P = 0.01). The 5-year freedom from PSA failure was only 25% for those patients with 3+ staining compared with 83% for those with 1+ staining (P = 0.02). The results of this pilot study have demonstrated that Tbeta15 staining intensity may be a potentially important marker to identify high-risk patients with moderately differentiated, clinically localized prostate cancer.

胸腺素β-15可预测临床局限性前列腺癌患者的远期失败——一项初步研究的结果。

报告一项关于新鉴定的肌动蛋白结合蛋白胸腺素β-15(tbeta 15)在预测Gleason 6/10临床局限性前列腺癌患者的前列腺特异性抗原(PSA)和骨衰竭中的预后价值的初步研究结果。本初步研究评估了32例(中位年龄70岁)患有临床局限性中分化(Gleason 6/10)前列腺癌的患者，这些患者在马萨诸塞州总医院接受了单独的外照射放疗(68.4 Gy)和可用的石蜡块。所有患者在最初表现时都患有临床分期的M0病，这由骨扫描(T1c-4，NX)记录。对相应的活检标本进行Tbeta15免疫组织化学染色，然后以盲法将tbeta 15与临床结果相关联。所有患者的中位随访时间为6年(1-19年)。32名患者的结果可分为三类:无疾病证据的患者(n = 11)，PSA失败但无骨衰竭记录的患者(n = 11)，PSA失败但有骨衰竭记录的患者(n = 10)。Tbeta15染色强度与临床结果密切相关。在那些标本染色为3+(最强染色)的患者中，62%发生骨衰竭，相比之下，那些标本染色为1+(最弱染色)的患者中发生骨衰竭的比例为13%(P = 0.01)。PSA失败的5年无病率在3+染色的患者中仅为25%,而在1+染色的患者中为83 %( P = 0.02)。这项初步研究的结果表明，Tbeta15染色强度可能是识别中度分化、临床局限性前列腺癌高危患者的潜在重要标志。